ResearcherJesse Brown VA Medical CenterActive in the last 2 years
Jeffrey H. Becker
Matched on ORCID iD 0000-0001-7645-2466; OpenAlex author ID A5072157650. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2024: 2 papers · 2025: none · 2026: 1 paper
Papers 3
- Exploiting Acquired Drug Resistance in Pancreatic Cancer through Selective Covalent Targeting of MAP2K4/7. Co-author DOI 10.1021/acschembio.6c00580↗
- Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-23-3574↗
- Trametinib Potentiates Anti-PD-1 Efficacy in Tumors Established from Chemotherapy-Primed Pancreatic Cancer Cells. Co-author DOI 10.1158/1535-7163.mct-23-0833↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Thao D. Pham · 3 shared papers, 2024–2026 · strength 0.76
- Paper Exploiting Acquired Drug Resistance in Pancreatic Cancer through Selective Covalent Targeting of MAP2K4/7. DOI 10.1021/acschembio.6c00580↗
- Paper Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer. DOI 10.1158/0008-5472.can-23-3574↗
- Paper Trametinib Potentiates Anti-PD-1 Efficacy in Tumors Established from Chemotherapy-Primed Pancreatic Cancer Cells. DOI 10.1158/1535-7163.mct-23-0833↗
- Hidayatullah G. Munshi · 3 shared papers, 2024–2026 · strength 0.76
- Paper Exploiting Acquired Drug Resistance in Pancreatic Cancer through Selective Covalent Targeting of MAP2K4/7. DOI 10.1021/acschembio.6c00580↗
- Paper Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer. DOI 10.1158/0008-5472.can-23-3574↗
- Paper Trametinib Potentiates Anti-PD-1 Efficacy in Tumors Established from Chemotherapy-Primed Pancreatic Cancer Cells. DOI 10.1158/1535-7163.mct-23-0833↗
- Mario A. Shields · 2 shared papers, 2024 · strength 0.45
- Paper Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer. DOI 10.1158/0008-5472.can-23-3574↗
- Paper Trametinib Potentiates Anti-PD-1 Efficacy in Tumors Established from Chemotherapy-Primed Pancreatic Cancer Cells. DOI 10.1158/1535-7163.mct-23-0833↗
- Gina M. Connors · 1 shared paper, 2026 · strength 0.32
- Karl A. Scheidt · 1 shared paper, 2026 · strength 0.32
- Daniel R. Principe · 1 shared paper, 2024 · strength 0.23
- Dhavan Shah · 1 shared paper, 2024 · strength 0.22
- David J. Bentrem · 1 shared paper, 2024 · strength 0.22
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.